药品原始创新模式演化及对中国的启示

The Evolution of Pharmaceutical Radical Innovation Mode to China

原始创新模式是原始创新活动的载体。中国本土创新主体依据自身现状选择合理的创新模式,对于实质性提升中国制药行业原始创新能力具有重要意义。通过梳理原始创新模式演化,归纳药品原始创新模式,考察影响原始创新模式选择的主要因素,进而研究中国制药行业原始创新的现状和不足。结果表明,中国本土药品创新模式单调,主要原因在于创新主体单一、基础研究累积薄弱、同质化竞争严重、缺乏可操作性的激励政策。中国政府应该引导更多的本国主体参与原始创新,鼓励主体间进行多元化合作,提高创新资源配置效率,并制定具有可操作性的激励政策。

Radical innovation mode is the vector for the radical innovation.Chinese native innovators choose the reasonable radical innovation mode based on its own conditions.It is great significance to improve radical innovation capability of China pharmaceutical industry.By hackling the evolution of the pharmaceutical radical innovation modes,concluding innovation mode,investigating the influencing factors for how to choose the radical innovation modes,the article studies the status and inferiors of Chinese pharmaceutical radical innovation.The results show that the diversification of the innovation modes and the innovators becomes a general trend.Chinese native pharmaceutical radical innovation mode is monotonic.The reason lies in innovator single,basic research accumulation weakness,excessive homogeneity competition,operating incentive policy lack.The government should promote the native subjects to participate in radical innovation,encourage the diversification cooperative with the subjects,improve the resource allocation efficiency and make the operating incentive policies.